Sanofi pulls leukaemia drug ahead of possible OK for Lemtrada

PARIS Mon Aug 20, 2012 10:19pm IST

Related Topics

Stocks

   

PARIS (Reuters) - Sanofi's rare disease unit Genzyme is pulling leukaemia drug Campath to prepare for its launch under a different dosage and as a multiple sclerosis treatment that will be branded as Lemtrada.

The withdrawal, meant to prevent the off-label use of Campath as a multiple sclerosis drug, is already under way in some European countries and will be effective in the United States on September 4, a Genzyme spokesman said.

Lemtrada, which Sanofi submitted for approval with health regulators in Europe and the United States in June, could be launched in 2013 if it wins approval.

If approved, it will be given far less frequently and in lower doses than Campath, and is one of the new products the French drugmaker is betting on to restore growth after losing several aging blockbusters to generic rivals.

"We think that this stoppage shows Sanofi's confidence in the approval of Lemtrada in multiple sclerosis," said Bryan Garnier analyst Eric Le Berrigaud, who estimates the drug could generate sales of $400 million in 2018, if approved.

The withdrawal will also enable Sanofi to adjust Lemtrada's price closer to that of rival multiple sclerosis drugs, Le Berrigaud said. Rivals include Tysabri, an injectable drug sold by Biogen Idec and Elan, while Novartis markets MS pill Gilenya.

Campath, which last year had sales of $76 million, will continue to be available through patient access programs in the 50 countries where it has been available since its launch in 2001.

"In most countries we will provide the drug for free, where this is permitted," the Genzyme spokesman said.

The news was first reported by trade publication BioCentury.

Sanofi shares, which have risen around 18 percent since the start of the year, closed 0.8 percent higher at 67.1 euros, outperforming France's main CAC-40 index, which closed 0.2 percent lower.

(Reporting by Elena Berton; Editing by David Cowell)

FILED UNDER:
  • Most Popular
  • Most Shared

REUTERS EXCLUSIVE

Biotech Leap

Biotech Leap

World's top drugmaker Novartis takes aim at tech  Full Article 

Bird Flu

Bird Flu

Bird flu found in UK, Netherlands but authorities say little risk to humans  Full Article 

Drug Abuse

Drug Abuse

‘Tweens’ most likely to misuse over-the-counter meds.  Full Article 

Nutrition Value

Nutrition Value

School lunches may be better than lunch packed at home.  Full Article 

Smoking Problem

Smoking Problem

U.S. youth smoking, increased use of e-cigarettes a worry: CDC.  Full Article 

No Progress

No Progress

Progress on eliminating measles has stalled, WHO warns.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage